Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Their purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.
IN Control education series
IN Control advanced course: INs and outs of INsulin INitiation and INtensification
This GP-led, on-demand advanced course, supported by diabetes specialists, will provide practical guidance on the role and implementation of insulin in the contemporary management of diabetes in the primary care space.
Individualising insulin options in type 2 diabetes: From initiation to intensification
Insulin therapy is a key part of glycaemic management in type 2 diabetes, and individualised treatment is central to providing optimal outcomes. This module outlines the tailored selection of insulin regimens for initiation and intensification, and the effective use of education and review to provide ongoing care.
IN Control clinical audit: INsulin INitiation and INtensification to avoid clinical INertia
Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.
Guide: Use of IDegAsp in T2D
Review practical recommendations from Australian diabetes experts on when and how to use IDegAsp (insulin degludec/insulin aspart) in real-world practice.
Podcast series: Improving care for patients with T2DM and the role of insulin
This series of podcasts aims to provide general practitioners (GPs) and other healthcare professionals with the latest clinically relevant information and opinions from experts in T2DM about the appropriate management of patients with T2DM in primary care, particularly regarding insulin therapy.
Insulin therapy case study quiz
Select the best management options for a type 2 diabetes patient on insulin therapy in this case study quiz.
Recently published consensus statement: Practical guidance for the use of IDegAsp in type 2 diabetes
Dr Sarah Glastras provides practical advice on the usage of the insulin degludec/insulin aspart coformulation, and outlines its role in insulin initiation and intensification in light of the recently released consensus statement.
